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Abstract Class-1 translation termination factors (release fac-
tors (RFs)) from Eukarya (eRF1) and Archaea (aRF1) exhibit a
high degree of amino acid sequence homology and share many
common motifs. In contrast to eRF1, function(s) of aRF1 have
not yet been studied in vitro. Here, we describe for the first time
the cloning and expression in Escherichia coli of the gene
encoding the peptide chain RF from the hyperthermophilic
archaeon Methanococcus jannaschii (MjaRF1). In an in vitro
assay with mammalian ribosomes, MjaRF1, which was over-
produced in E. coli, was active as a RF with all three termination
codon-containing tetraplets, demonstrating the functional resem-
blance of aRF1 and eRF1. This observation confirms the earlier
prediction that eRF1 and aRF1 form a common structural^
functional eRF1/aRF1 protein family, originating from a
common ancient ancestor.
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1. Introduction
Termination of protein synthesis is carried out on the ribo-
some with the help of two key components, the termination
codon in the mRNA encountering the A site and the class-1
polypeptide chain release factor (RF) inducing peptidyl-tRNA
hydrolysis (for reviews, see [1^4]). In bacteria, RF1 decodes
the stop codons UAG and UAA and RF2 decodes UGA and
UAA. Mitochondrial RFs from Eukarya belong to the bacte-
rial type both structurally and functionally. In Eukarya, only
one class-1 factor, eRF1, was found which decodes all three
termination codons [5,6]. In all Archaea, where the complete
sequence of the genome is available, only one gene encoding a
peptide chain RF, aRF1, was identi¢ed so far [7^10]. The
aRF1 family is highly homologous to the eRF1 family, indi-
cating a common origin and ancestor molecule [3,4,11^13].
For this reason, eRF1 and aRF1 sequences were joined into
a single protein family, entirely di¡erent from the bacterial/
mitochondrial family RF1/2/mit [6,12].
The close structural similarity between eukaryal and archae-
al RFs led to the assumption that these proteins could also be
functionally related [14]. In particular, aRF1 may recognize
all three stop codons and function with eukaryotic ribosomes.
Up to now, this hypothesis had not been tested, as, to the best
of our knowledge, no aRF1 had been isolated from any
archaeal species or cloned and expressed as a recombinant
protein.
The aim of this work was to clone and to express the aRF1
gene from the hyperthermophilic archaeon Methanococcus
jannaschii. The puri¢ed factor was shown to possess an in
vitro release activity with mammalian ribosomes toward all
three termination codons, proving for the ¢rst time functional
compatibility for eukaryal and archaeal translation termina-
tion machineries.
2. Materials and methods
2.1. Cloning and overexpression of the aRF gene from M. jannaschii
In order to clone the gene encoding MjaRF1 into the regulated
expression vector pET11a, the corresponding DNA fragments were
generated by PCR. Synthetic oligonucleotides were obtained from
MWG-Biotech (Ebersburg, Germany): 5P-CTCATGGTGATACA-
TATGGCATCAACTGATTC-3P (corresponding to the 5P end of
the aRF gene), 5P-GCATAAATTTGAAGGGATCCAGGAGTTAT-
TGAT-3P (corresponding to the 3P end). The primer complementary
to the 5P end of the gene contains the initiator ATG codon. The NdeI
site and the BamHI site created for inserting the MjaRF1 gene into
pET11a [15] are underlined. Plasmid AMJHW52 (available from
ATCC) carrying the MjaRF1 gene was used as template for PCR.
For the PCR reactions, the Advantage cDNA Polymerase Mix (Clon-
tech, Palo Alto, CA, USA), which provides an antibody-mediated ‘hot
start’ and a proofreading activity, was used. The reaction mixture
contained 10 ng of template DNA, 50 pmol of each primer, 200 WM
of each of the four deoxynucleotide triphosphates, 1 Wl of the poly-
merase mix, and the PCR bu¡er supplied by the manufacturer, in a
total volume of 50 Wl. Ampli¢cation was allowed to proceed through
30 cycles at 94‡C (30 s), 50‡C (30 s) and 72‡C (1 min). The ampli¢ed
DNA was digested with NdeI and BamHI and subcloned into
pET11a. The correct sequence of the resulting plasmid, pMjaRF1.4,
was con¢rmed by double-stranded DNA sequencing.
2.2. Overproduction and puri¢cation of aRF1
In the aRF1 gene of M. jannaschii, the codons mainly used for
arginine are AGG and AGA (18 codons) and that for isoleucine is
AUA (13 codons). These are the less frequently used codons in
Escherichia coli. To obtain maximal yields and to avoid a potential
high-level misincorporation of amino acids (e.g. lysine instead of ar-
ginine [16]) when MjaRF1 is overexpressed in large amounts from
pMjaRF1.4, we used the E. coli expression strain BL21-Codon-
Plus(DE3)-RIL which carries extra copies of the tRNA genes recog-
nizing AGA/AGG and AUA [17]. After induction with isopropyl-L-
thiogalactopyranoside (IPTG) (1 mM ¢nal concentration), cells were
grown for an additional 3 h, harvested by centrifugation and resus-
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pended in a bu¡er containing 50 mM Tris^HCl, pH 7.6, 0.8 M NaCl,
150 mM MgCl2, 5 mM L-mercaptoethanol, 0.1 mM phenylmethylsul-
fonyl£uoride (PMSF). After a double passage through a chilled
French pressure cell at 10 000 lb/in2, E. coli cell debris was removed
by centrifugation (11 000Ug for 30 min). The supernatant was then
heated at 90‡C for 20 min and the denatured E. coli proteins removed
by centrifugation at 10 000Ug for 1 h at 4‡C. MjaRF1 was retained in
the soluble fraction.
The supernatant containing MjaRF1 was diluted 16-fold to a ¢nal
concentration of 50 mM NaCl and loaded onto a SP-Sepharose Fast
Flow (Pharmacia) column. The column was equilibrated with 50 mM
Tris^HCl, pH 7.6, 0.05 M NaCl, 1 mM 1,4-dithiothreitol (DTT),
0.1 mM PMSF. After washing with the equilibration bu¡er, the pro-
tein was eluted at 4‡C with a linear gradient of 0.05^1.2 M NaCl. This
step allows separation of the protein from RNA contamination. Frac-
tions containing MjaRF1 were collected, pooled, diluted with 50 mM
NaAc, pH 5.5, 1 M (NH4)2SO4, 1 mM DTT, 0.1 mM PMSF, and
applied to a Butyl-Sepharose Fast Flow (Pharmacia) column. The
protein was eluted with a linear gradient of 1^0 M (NH4)2SO4. After
this step, the protein was approximately 80% pure. Fractions contain-
ing MjaRF1 were collected, pooled and the protein precipitated with
ammonium sulfate (55% saturation) at 4‡C. The protein pellet was
dissolved in a bu¡er containing 50 mM Tris^HCl, pH 7.6, 25 mM
NaCl, 1 mM DTT, 0.1 mM PMSF and loaded onto a DEAE-Sephar-
ose (Pharmacia) column. Protein was eluted with a linear gradient of
0.025^1 M NaCl. The purity of the resulting MjaRF1 preparation was
greater than 95% as estimated by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE). The concentration of the
protein was determined with the Bio-Rad protein assay, using bovine
serum albumin as a standard.
2.3. Overproduction and puri¢cation of human eRF1 protein
Plasmid pQE-30 carrying the full-length cDNA encoding human
eRF1 was used to produce eRF1 in E. coli M15(pREP4) [13]. Protein
expression was induced by adding IPTG to a ¢nal concentration of
0.4 mM. The bacterial pellet was resuspended in lysis bu¡er contain-
ing 50 mM Tris^HCl, pH 7.5, 0.2 M KCl, 10 mM imidazole, 1%
Nonidet P40, 10% glycerol, 2 mM L-mercaptoethanol, 1 mM PMSF
and 0.2 mg/ml of lysozyme, incubated 15 min at room temperature
(RT), sonicated and centrifuged at 10 000Ug for 30 min. Then, 150 ml
of Talon1 metal a⁄nity resin (Clontech) equilibrated with bu¡er A
(20 mM Tris^HCl, pH 8.0, 0.2 M KCl, 10% glycerol) containing
10 mM imidazole was added to the supernatants. After 30 min in-
cubation at RT, the Talon1 suspension was transferred onto a col-
umn and the resin washed with 10 volumes of bu¡er A containing
10 mM imidazole. His-tagged protein was eluted with bu¡er A con-
taining 0.1 M imidazole; 0.2 ml fractions were collected and analyzed
by 10% SDS^PAGE. Protein-containing fractions were pooled and
dialyzed against 50 mM Tris^HCl, pH 7.5, 50 mM KCl, 10% glycerol,
0.1 mM EDTA and 1 mM DTT. Protein concentration was deter-
mined as described above.
2.4. Assays for eRF1 and aRF1 activities in vitro
The eRF1 and aRF1 release activities were measured in an in vitro
assay, as hydrolysis of f[35S]Met-tRNAMetf associated with 80S ribo-
somes programmed with one of three mini-mRNAs, UUCAU-
GUAAA, UUCAUGUAGA or UUCAUGUGAA (synthesized by
A. Veniaminova and M. Ryabkova, Novosibirsk State University),
containing the initiation (AUG) and termination (underlined) codons
[18]. Incubation mixtures (25 Wl) contained 20 mM Tris^HCl, pH 7.5,
10 mM MgCl2, 8 mM NH4Cl and 1.5 pmol of f[35S]Met-
tRNAMetf Wmini-mRNAWribosome complex. The concentration of the
human eRF1 or aRF1 was 0.3 mM. The amount of f[35S]Met released
at zero time (1000^1200 cpm) was subtracted from all values. Isola-
tion of rabbit reticulocyte ribosomal subunits was described previ-
ously [19,20].
3. Results and discussion
On the basis of the nucleotide sequence, aRF1 from M.
jannaschii was predicted to be a protein of 425 amino acids
[7]. Inspection of the DNA sequence located upstream of the
assigned AUG initiation codon revealed that the proposed
start codon is not preceded by any Shine^Dalgarno-like se-
quence. The second in-frame AUG triplet, which is located
four codons downstream, is preceded at the appropriate dis-
tance of four nucleotides by a ribosome binding sequence
(GGTGAT) complementary to the 3P end of 16S rRNA.
Therefore, we assume that the second in-frame AUG codon
is used as a start codon. This notion is supported by the
alignment of RF1 factors. The N-terminus of the shorter,
421 amino acid long protein is in perfect agreement with
that of the related Archaea Methanobacterium thermoautotro-
phicum [10] and Pyrococcus horikoshii [8].
An incorrect assignation of the initiation codon has been
demonstrated for several genes encoding archaeal ribosomal
proteins [21]. Dennis [14] suggested that many of the assigned
start codons lacking a Shine^Dalgarno sequence may be in-
correct, as methanogenic Archaea, in general, use Shine^Dal-
garno sequences to identify AUG, GUG or UUG codons as
initiation codons.
Fig. 1 shows the result of overexpression of the MjaRF1
gene in E. coli and puri¢cation of the overproduced protein.
The size of the protein induced in the recombinant strain (lane
3) corresponds to the molecular mass (47 500) calculated from
the deduced amino acid sequence of MjaRF1 [7]. The advant-
age of M. jannaschii aRF1 puri¢cation over puri¢cation of
mesophilic recombinant proteins stems from the hyperthermo-
philic nature of this organism. A protein denaturing step re-
moving most of the E. coli proteins could be included (Fig. 1,
lanes 6 and 7). Apart from its simplicity, it also inactivates the
host proteins which may interfere with further protein puri¢-
cation (e.g. proteases). The combination of ion-exchange and
hydrophobic chromatography steps resulted in puri¢cation of
MjaRF1 of greater than 95% (Fig. 1, lane 8), which was
su⁄cient to run further functional tests.
Puri¢ed human and Xenopus laevis eRF1 are active in vitro
with each of the three stop codon-containing tetraplets and
rabbit ribosomes [6]. Under the same experimental conditions,
pure aRF1 from M. jannaschii was fully active (Table 1). The
ability of aRF1 to respond to all three termination codons
clearly distinguishes aRF1 from the bacterial/mitochondrial
RF1/2/mit family, where any factor is unable to decode
more than two termination codons.
Surprisingly, the activity of M. jannaschii aRF1 with rabbit
Fig. 1. Overproduction and puri¢cation of RF aRF1 from M. jan-
naschii. A 15% SDS^polyacrylamide gel stained with Coomassie
blue is presented. Lane 1, total cellular protein from E. coli
BL21(DE3); lane 2, total cellular protein from E. coli BL21(DE3)
transformed with pMjaRF1.4, before induction with IPTG; lane 3,
overproduction of aRF1 in E. coli BL21(DE3) carrying pMjaRF1.4
(total cellular protein 6 h after induction with IPTG); lane 4, super-
natant after cell destruction; lane 5, corresponding cell debris pellet;
lane 6, supernatant after heat step; lane 7, pellet after heat step (de-
natured E. coli proteins); lane 8, puri¢ed MjaRF1.
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ribosomes was virtually identical to that of eRF1 for all three
stop codons, though the optimal growth temperature of the
hyperthermophilic archaeon M. jannaschii and that of mam-
mals di¡ers by about 50‡C. Despite that, aRF1 is active even
at 37‡C. Since recombinant E. coli was grown at 37‡C, but the
extract was then heated to 90‡C (see Section 2), it remains
unknown whether the biologically active folding of M. janna-
schii aRF1 proceeded at normal or elevated temperatures.
One of the puzzling problems of protein structures is the
identi¢cation of amino acids which confer thermostability to
the protein molecule. The aRF1 family includes not only ther-
mophilic but also mesophilic proteins. Therefore, the eRF1/
aRF1 family may become a very useful model system for
delineation of a structural basis of thermosensitivity/stability.
Studying hybrid translational systems provides insight into
the functional and structural similarity of ribosomes and
translational factors from di¡erent phylogenetic kingdoms.
The functional compatibility of mammalian ribosomes with
archaeal RF1, described here, suggests that the architecture
of the binding site for class-1 RFs is identical or very similar
in archaeal and eukaryal ribosomes, and that the overall
shape of eRF1 and aRF1 molecules should also be very sim-
ilar.
An amino acid sequence alignment of human eRF1 and
aRF1 from M. jannaschii shows that the N-terminus of
MjaRF1 is ¢ve amino acids shorter than human eRF1 and
that the N-termini (up to amino acid residue 18) show very
little identity (Fig. 2). Nevertheless, both factors are active
with mammalian ribosomes demonstrating that the N-termi-
nal variable region in the eRF1/aRF1 family is not essential
for function. This result is fully consistent with the earlier
observation that deletion of the ¢rst 20 N-terminal amino
acid residues in human eRF1 causes no change in its func-
tional activity [18].
At the C-terminus, aRF from M. jannaschii is 18 amino
acids shorter than human eRF1 (Fig. 2), but this natural
‘truncation’ does not abolish RF activity, demonstrating
that the C-terminal amino acids are not involved in mainte-
Table 1
Release activity of puri¢ed human eRF1 and MjaRF1 with rabbit
ribosomes programmed with stop codon-containing tetranucleotides
Termination factor f[35S]Met released (cpm)
Mini-mRNA containing stop codon
UAA UAG UGA
Human eRF1 3000 4060 2350
M. jannaschii aRF1 2600 3700 2530
For experimental details, see Section 2.
Fig. 2. Amino acid sequence alignment of human eRF1 (SWISS-PROT Acc. P46055) and MjaRF1 (SWISS-PROT Acc. Q58239). Strictly con-
served residues are boxed in black.
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nance of RF activity. Our data on the release activity of
MjaRF1 contradict the assumption that, in yeast eRF1/
Sup45p, the homolog of human eRF1, the C-terminal acidic
amino acids are essential for its function [22,23]. Our obser-
vation is consistent with earlier data showing that deletion of
the 22 C-terminal amino acids in human eRF1 did not inter-
fere with eRF1 binding to eRF3 [24] and with an in vitro RF
activity [18]. Within the human eRF1 electron density map,
determined recently [25], these residues are disordered and are
assumed to be mobile regions of the protein.
Deletion of residues 411^415, which are highly conserved in
Eukarya and Archaea [12,24], abolishes the ability of eRF1 to
interact with eRF3. No genes homologous to eRF3 have yet
been found in archaeal genomes [7^10]. However, the high
degree of homology with the eRF3 binding region of eukaryal
eRF1 suggests that aRF1 could form a complex with eRF3.
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